Woodline Partners’s 10x Genomics TXG Stock Holding History

Woodline Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-105,261	Closed	-$3.95M	–	674
2024 Q1	$3.95M	Buy	+105,261	New	+$4.62M	0.04%	384
2023 Q4	–	Sell	-151,098	Closed	-$6.23M	–	658
2023 Q3	$6.23M	Buy	+151,098	New	+$7.86M	0.07%	284
2023 Q2	–	Sell	-61,270	Closed	-$3.42M	–	754
2023 Q1	$3.42M	Sell	61,270 -142,784	-70%	-$6.67M	0.05%	344
2022 Q4	$7.44M	Buy	+204,054	New	+$6.67M	0.1%	257

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Woodline Partners's TXG Position: Q2 2024 in Review

Woodline Partners sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 105,261 shares — an estimated $3.95M sold.

Woodline Partners first reported a position in TXG in Q4 2022 and held it in 4 quarters. The position peaked at $7.44M in Q4 2022. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

Woodline Partners reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
Woodline Partners sold 105,261 10x Genomics shares in Q2 2024, an estimated $3.95M.
Woodline Partners first reported a position in 10x Genomics in Q4 2022 and held it in 4 quarters.
Woodline Partners's 10x Genomics position peaked at $7.44M in Q4 2022.
261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Woodline Partners's 13F filing for Q2 2024, filed 14 Aug 2024.